Navigation Links
Isis Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference
Date:3/2/2010

CARLSBAD, Calif., March 2 /PRNewswire-FirstCall/ --Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Cowen's 30th Annual Health Care Conference on Monday, March 8, 2010 at 2:30 p.m. ET at The Boston Marriott Copley Place.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 22 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide.  Additional information about Isis is available at www.isispharm.com.

SOURCE Isis Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.isispharm.com

'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
2. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
3. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
4. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
5. Ferring Pharmaceuticals and Gene Security Network Partner to Test Advanced Preimplantation Genetic Diagnosis (PGD) Technology
6. Pharmaceutical Industry Veteran is Appointed CMO at Kinex Pharmaceuticals
7. Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer
8. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results
9. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
10. Jazz Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on March 3, 2010
11. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... ORLANDO, Fla. , July 17, 2017  MedX ... - branded medical testing, strengthening and rehabilitation equipment, today ... Back Machine Program. MedX is considered the gold standard ... world leader in specialized medical strengthening equipment. ... into a lease with the physician or practice who ...
(Date:7/13/2017)... 2017  Centurion Medical Products, a leader in medical product innovation ... impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part of ... patient pain while preventing unneeded emergency department admission due to severe ...
(Date:7/12/2017)... , July 12, 2017  Eli Lilly and Company ... agreement with generic companies to resolve pending patent litigation in ... Virginia regarding the Cialis ® (tadalafil) ... on April 26, 2020. As part of the agreement, Cialis ... September 27, 2018. "The unit dose patent for ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... The Ellis Agency, an eastern Georgie ... Foundation in a community wide charity event with the goal of bringing in support ... local woman who lives with epilepsy, recently launched a charity campaign of her own ...
(Date:7/21/2017)... ... July 21, 2017 , ... Thomas Jefferson University , ... was awarded a $300,000 grant from The Pew Center for Arts & Heritage ... and the recognition of one’s own limits among health professions students. , ...
(Date:7/21/2017)... NJ (PRWEB) , ... July 21, 2017 , ... ... has received a $5,000 grant from the C. R. Bard Foundation, ... Day Center at Somerset Hills , a service available through the nonprofit home ...
(Date:7/21/2017)... CANADA (PRWEB) , ... July 21, 2017 , ... ... 80% follow-up at 10 years, researchers from the Multicenter Orthopaedics Outcome Network (MOON) ... of life a decade after surgery, though activity levels decline over time. The ...
(Date:7/20/2017)... MA (PRWEB) , ... July 20, 2017 , ... ... form of blood and bone marrow cancer that progresses rapidly without treatment. Newly ... recommended to reduce the chance of reoccurrence and relapse. With such a ...
Breaking Medicine News(10 mins):